跳至主要内容
临床试验/NL-OMON43221
NL-OMON43221已完成不适用

A single center, randomized, open-label, controlled, three-arm study to evaluate the effect of a new combined oral contraceptive (COC) containing 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP) and of two reference COCs containing either 30 mcg Ethinylestradiol (EE) and 150 mcg Levonorgestrel (LNG) or 20 mcg EE and 3 mg DRSP on endocrine function, metabolic control and hemostasis during 6 treatment cycles - E4/DRSP endocrine function, metabolic control and hemostasis study

Estetra SPR0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
100